Developer docs
API playgroundTry for free, no card

Search company profiles

JUNO Genetics

Full company profile

uuid000cjog

Namestring
JUNO Genetics
Legal namestring
Juno Genetics, US Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Juno Genetics is a privately held specialty diagnostics laboratory that provides preimplantation genetic testing (PGT) for patients undergoing in vitro fertilization (IVF). Operating as Juno Genetics, US Inc. with its US headquarters in Basking Ridge, New Jersey and a firmographic base in Oxford, United Kingdom, the company serves two primary segments: IVF patients referred by fertility healthcare providers, and the clinics and reproductive endocrinologists who direct those referrals. Service is delivered through a B2B2C model in which Juno is embedded into clinic workflows, with direct patient scheduling and genetic counseling layered on top of laboratory testing.

The company's core offering is the PGTseq franchise of three tests: PGTseq-A for aneuploidy screening, PGTseq-M for customized single-gene disorder testing, and PGTseq-SR for chromosome rearrangement testing. The underlying platform combines targeted next-generation sequencing (tNGS) with single nucleotide polymorphism (SNP) assays, explicitly avoiding whole-genome amplification. Juno claims greater than 98% accuracy in whole-chromosome aneuploidy and unbalanced rearrangement screening, supported by two validation studies: a non-selection embryo transfer study and a blinded rebiopsy study showing 97-99% concordance. Cumulative testing volume is stated in the hundreds of thousands of embryos, generating a meaningful clinical-outcome dataset.

Juno generates revenue through professional-services fees for laboratory testing, with pricing not publicly disclosed. Distribution runs through IVF clinic referrals across five regional markets — USA, UK, Spain, Italy and broader Europe — each with its own localized website. Patient-facing capabilities include board-certified genetic counseling appointments and direct contact channels, but the company does not appear to publish enterprise contract terms, recurring-revenue metrics, or funding history. Strategic positioning emphasizes clinical evidence and validation depth over marketing-driven claims.

Short descriptiontext

Juno Genetics is a specialty diagnostics laboratory providing preimplantation genetic testing (PGTseq-A, PGTseq-M, PGTseq-SR) using targeted NGS and SNP assays to IVF patients and fertility clinics across the US, UK, Spain, Italy and broader Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersValencia, Spain
HQ citystring
Valencia
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preimplantation genetic testing, IVF genetic screening, aneuploidy screening services, single gene disorder testing, chromosome rearrangement testing
Industry4 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Reproductive Genetic Testing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preimplantation Genetic Testing Services
TypeProfessional Services
Description

Laboratory diagnostic services providing PGTseq-A, PGTseq-M, and PGTseq-SR testing for IVF patients. Services are provided to patients undergoing fertility treatments through referral from healthcare providers.

junogenetics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

JUNO Genetics is a specialized reproductive diagnostics laboratory that performs preimplantation genetic testing (PGT) on embryo biopsy samples from IVF cycles. Its commercial offerings consist of three proprietary genetic tests — PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (structural chromosome rearrangement testing) — delivered together with genetic counseling services to fertility clinics, reproductive endocrinologists, and their patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Greater than 98% accuracy in screening for whole chromosome aneuploidy (PGTseq-A) and unbalanced chromosome rearrangements (PGTseq-SR)
+3 more records
Product overview1 text field

Juno Genetics operates a state-of-the-art laboratory specializing in preimplantation genetic testing (PGT) with three core genetic tests: PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (chromosome rearrangement testing). These tests are designed to inform IVF decisions by assessing embryo genetic health. The company also provides genetic counseling services as part of its patient support offering. All three PGT tests utilize targeted next-generation sequencing (tNGS) technology and SNP analysis for enhanced accuracy and quality control.

Product and service4 records
1PGTseq-A
CategoryReproductive Genetic Testing
Description

Preimplantation Genetic Testing for Aneuploidy (PGT-A) using targeted next-generation sequencing (tNGS) and SNP assays to identify embryos with the correct number of chromosomes during IVF; reported as greater than 98% accurate in screening for whole chromosome aneuploidy and including SNP-based molecular fertilization check, contamination detection, and embryo sibling QC. Designed for IVF patients referred by fertility clinics and reproductive endocrinologists.

2PGTseq-M
CategoryReproductive Genetic Testing
Description

Customized single gene disorder testing that is designed per family to detect genetic alterations associated with specific monogenic disorders in embryos prior to transfer during an IVF cycle; all embryos tested also receive aneuploidy screening with PGTseq-A. Targeted at individuals or couples with a known increased risk of transmitting a specific genetic condition.

3PGTseq-SR
CategoryReproductive Genetic Testing
Description

Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) performed via targeted next-generation sequencing (tNGS) to determine whether embryo biopsies have extra or missing chromosomal material in patients carrying a chromosome rearrangement; reported as greater than 98% accurate and bundling PGTseq-A aneuploidy screening.

4Genetic Counseling Services
CategoryGenetic Counseling
Description

Comprehensive patient support service offering access to board-certified genetic counselors on staff, easy scheduling, and payment assistance throughout the preimplantation genetic testing process; intended for IVF patients undergoing PGT through Juno Genetics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Top IVF Clinics and Reproductive Endocrinologists
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strong collaboration with top IVF clinics and reproductive endocrinologists to provide preimplantation genetic testing services. Juno works closely with fertility healthcare providers in supporting patients undergoing IVF treatments.

junogenetics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public US genetics company (NASDAQ: NTRA) with a dedicated reproductive health franchise including Empower (PGx), Spectrum PGT-A/M, and Vistara single-gene PGT. Competes head-to-head with Juno on IVF clinic contracts in the US.

TypeBroad incumbent
Description

Large US clinical laboratory offering women's health and reproductive genetics panels including NIPT and carrier screening. Broader incumbent that competes for the same fertility clinic referral channels, though not a PGT specialist.

3Genomic Prediction
TypeDirect peer
Description

US-based PGT laboratory offering PGT-A and polygenic PGT services. Direct competitor on aneuploidy screening with overlapping IVF clinic customer base, though differentiated by focus on polygenic risk scoring.

TypeBroad incumbent
Description

US clinical laboratory providing reproductive and women's health genetic testing services. Larger incumbent with established hospital and clinic relationships that overlap with Juno's IVF clinic customer base.

TypeEmerging player
Description

Emerging PGT provider focused on polygenic and single-gene embryo assessment. Partial product overlap with Juno's PGTseq-M and chromosome-level tests, targeting similar reproductive endocrinology customers.

6Reprogenetics (Labcorp)
TypeBroad incumbent
Description

Reprogenetics, now part of Labcorp, has historically been one of the largest PGT providers worldwide. Broader incumbent with deep IVF clinic penetration and significantly larger clinical lab infrastructure than Juno.

TypeDirect peer
Description

PGT laboratory offering PGT-A and PGT-SR to IVF clinics. Smaller direct peer with similar tNGS-based technology approach and comparable B2B clinic distribution model to Juno Genetics.

TypeDirect peer
Description

CooperSurgical's CooperGenomics division provides PGT-A, PGT-M, and PGT-SR services through IVF clinics globally. Directly comparable product suite and clinic-channel distribution model to Juno Genetics.

TypeOthers
Description

Supplies NGS instruments, reagents, and Ion Torrent-based PGT workflows used by many IVF genetics labs. Functions as an enabling technology provider to the PGT category in which Juno competes rather than a direct clinical competitor.

TypeDirect peer
Description

Spanish-origin PGT and reproductive genetics laboratory, acquired by Vitrolife in 2021 for ~$1.2B. Direct competitor offering PGT-A, PGT-M, and PGT-SR with international clinic network reach closely matching Juno's product portfolio and B2B2C IVF clinic model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JUNO Genetics

Reproductive Genetic Testingjunogenetics.com

Juno Genetics is a specialty diagnostics laboratory providing preimplantation genetic testing (PGTseq-A, PGTseq-M, PGTseq-SR) using targeted NGS and SNP assays to IVF patients and fertility clinics across the US, UK, Spain, Italy and broader Europe.

What JUNO Genetics does

Juno Genetics is a privately held specialty diagnostics laboratory that provides preimplantation genetic testing (PGT) for patients undergoing in vitro fertilization (IVF). Operating as Juno Genetics, US Inc. with its US headquarters in Basking Ridge, New Jersey and a firmographic base in Oxford, United Kingdom, the company serves two primary segments: IVF patients referred by fertility healthcare providers, and the clinics and reproductive endocrinologists who direct those referrals. Service is delivered through a B2B2C model in which Juno is embedded into clinic workflows, with direct patient scheduling and genetic counseling layered on top of laboratory testing.

The company's core offering is the PGTseq franchise of three tests: PGTseq-A for aneuploidy screening, PGTseq-M for customized single-gene disorder testing, and PGTseq-SR for chromosome rearrangement testing. The underlying platform combines targeted next-generation sequencing (tNGS) with single nucleotide polymorphism (SNP) assays, explicitly avoiding whole-genome amplification. Juno claims greater than 98% accuracy in whole-chromosome aneuploidy and unbalanced rearrangement screening, supported by two validation studies: a non-selection embryo transfer study and a blinded rebiopsy study showing 97-99% concordance. Cumulative testing volume is stated in the hundreds of thousands of embryos, generating a meaningful clinical-outcome dataset.

Juno generates revenue through professional-services fees for laboratory testing, with pricing not publicly disclosed. Distribution runs through IVF clinic referrals across five regional markets — USA, UK, Spain, Italy and broader Europe — each with its own localized website. Patient-facing capabilities include board-certified genetic counseling appointments and direct contact channels, but the company does not appear to publish enterprise contract terms, recurring-revenue metrics, or funding history. Strategic positioning emphasizes clinical evidence and validation depth over marketing-driven claims.

JUNO Genetics firmographics

Firmographics
Name
JUNO Genetics
Legal name
Juno Genetics, US Inc.
Website
https://junogenetics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Juno Genetics is a specialty diagnostics laboratory providing preimplantation genetic testing (PGTseq-A, PGTseq-M, PGTseq-SR) using targeted NGS and SNP assays to IVF patients and fertility clinics across the US, UK, Spain, Italy and broader Europe.
Ownership category
akta.pro rank

JUNO Genetics industry classification

Industry
Product category
Reproductive Genetic Testing
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Preimplantation genetic testing
  • IVF genetic screening
  • Aneuploidy screening services
  • Single gene disorder testing
  • Chromosome rearrangement testing

Where JUNO Genetics is headquartered

Location

Headquarters

HQ city
Valencia
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

JUNO Genetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Preimplantation Genetic Testing Services: Laboratory diagnostic services providing PGTseq-A, PGTseq-M, and PGTseq-SR testing for IVF patients. Services are provided to patients undergoing fertility treatments through referral from healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

JUNO Genetics product offering

Product offering

Core offering

JUNO Genetics is a specialized reproductive diagnostics laboratory that performs preimplantation genetic testing (PGT) on embryo biopsy samples from IVF cycles. Its commercial offerings consist of three proprietary genetic tests — PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (structural chromosome rearrangement testing) — delivered together with genetic counseling services to fertility clinics, reproductive endocrinologists, and their patients.

Product overview

Juno Genetics operates a state-of-the-art laboratory specializing in preimplantation genetic testing (PGT) with three core genetic tests: PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (chromosome rearrangement testing). These tests are designed to inform IVF decisions by assessing embryo genetic health. The company also provides genetic counseling services as part of its patient support offering. All three PGT tests utilize targeted next-generation sequencing (tNGS) technology and SNP analysis for enhanced accuracy and quality control.

Differentiator

Problem solved

Functional benefit

Products and services

  • PGTseq-A Preimplantation Genetic Testing for Aneuploidy (PGT-A) using targeted next-generation sequencing (tNGS) and SNP assays to identify embryos with the correct number of chromosomes during IVF; reported as greater than 98% accurate in screening for whole chromosome aneuploidy and including SNP-based molecular fertilization check, contamination detection, and embryo sibling QC. Designed for IVF patients referred by fertility clinics and reproductive endocrinologists.
  • PGTseq-M Customized single gene disorder testing that is designed per family to detect genetic alterations associated with specific monogenic disorders in embryos prior to transfer during an IVF cycle; all embryos tested also receive aneuploidy screening with PGTseq-A. Targeted at individuals or couples with a known increased risk of transmitting a specific genetic condition.
  • PGTseq-SR Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) performed via targeted next-generation sequencing (tNGS) to determine whether embryo biopsies have extra or missing chromosomal material in patients carrying a chromosome rearrangement; reported as greater than 98% accurate and bundling PGTseq-A aneuploidy screening.
  • Genetic Counseling Services Comprehensive patient support service offering access to board-certified genetic counselors on staff, easy scheduling, and payment assistance throughout the preimplantation genetic testing process; intended for IVF patients undergoing PGT through Juno Genetics.

Quantifiable outcome

  • Greater than 98% accuracy in screening for whole chromosome aneuploidy (PGTseq-A) and unbalanced chromosome rearrangements (PGTseq-SR)
  • +3 more outcomes

Companies that use JUNO Genetics

Customer profile

Segments4 records

Ideal customer profiles3 records

JUNO Genetics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

JUNO Genetics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Top IVF Clinics and Reproductive EndocrinologistscoreStrategic or Co-development PartnerStrong collaboration with top IVF clinics and reproductive endocrinologists to provide preimplantation genetic testing services. Juno works closely with fertility healthcare providers in supporting patients undergoing IVF treatments.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

JUNO Genetics competitors and assessment

Company assessment

Direct peers

  • Natera: Public US genetics company (NASDAQ: NTRA) with a dedicated reproductive health franchise including Empower (PGx), Spectrum PGT-A/M, and Vistara single-gene PGT. Competes head-to-head with Juno on IVF clinic contracts in the US.
  • Genomic Prediction: US-based PGT laboratory offering PGT-A and polygenic PGT services. Direct competitor on aneuploidy screening with overlapping IVF clinic customer base, though differentiated by focus on polygenic risk scoring.
  • Progenesis: PGT laboratory offering PGT-A and PGT-SR to IVF clinics. Smaller direct peer with similar tNGS-based technology approach and comparable B2B clinic distribution model to Juno Genetics.
  • CooperSurgical (CooperGenomics): CooperSurgical's CooperGenomics division provides PGT-A, PGT-M, and PGT-SR services through IVF clinics globally. Directly comparable product suite and clinic-channel distribution model to Juno Genetics.
  • Igenomix (Vitrolife): Spanish-origin PGT and reproductive genetics laboratory, acquired by Vitrolife in 2021 for ~$1.2B. Direct competitor offering PGT-A, PGT-M, and PGT-SR with international clinic network reach closely matching Juno's product portfolio and B2B2C IVF clinic model.

Broad incumbents

  • Quest Diagnostics: Large US clinical laboratory offering women's health and reproductive genetics panels including NIPT and carrier screening. Broader incumbent that competes for the same fertility clinic referral channels, though not a PGT specialist.
  • BioReference Laboratories (OPKO Health): US clinical laboratory providing reproductive and women's health genetic testing services. Larger incumbent with established hospital and clinic relationships that overlap with Juno's IVF clinic customer base.
  • Reprogenetics (Labcorp): Reprogenetics, now part of Labcorp, has historically been one of the largest PGT providers worldwide. Broader incumbent with deep IVF clinic penetration and significantly larger clinical lab infrastructure than Juno.

Emerging players

  • Myome Sciences: Emerging PGT provider focused on polygenic and single-gene embryo assessment. Partial product overlap with Juno's PGTseq-M and chromosome-level tests, targeting similar reproductive endocrinology customers.

Others

  • Thermo Fisher Scientific (Reproductive Health): Supplies NGS instruments, reagents, and Ion Torrent-based PGT workflows used by many IVF genetics labs. Functions as an enabling technology provider to the PGT category in which Juno competes rather than a direct clinical competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

JUNO Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JUNO Genetics leadership team

Management profile

Number of profiles

Profiles1 record

JUNO Genetics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JUNO Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JUNO Genetics

What does JUNO Genetics do?

JUNO Genetics is a specialized reproductive diagnostics laboratory that performs preimplantation genetic testing (PGT) on embryo biopsy samples from IVF cycles. Its commercial offerings consist of three proprietary genetic tests — PGTseq-A (aneuploidy screening), PGTseq-M (single gene disorder testing), and PGTseq-SR (structural chromosome rearrangement testing) — delivered together with genetic counseling services to fertility clinics, reproductive endocrinologists, and their patients.

Is JUNO Genetics a public or private company?

JUNO Genetics is a private company. It is classified as unknown and is currently operating.

When was JUNO Genetics founded?

JUNO Genetics was founded in 2018. It employs 11 to 50 people.

Where is JUNO Genetics based?

JUNO Genetics is headquartered in Valencia, Spain, in the Europe region.

How does JUNO Genetics make money?

One revenue line is on record: preimplantation Genetic Testing Services.

Who are JUNO Genetics's main competitors?

Direct peers on record are Natera, Genomic Prediction, Progenesis, CooperSurgical (CooperGenomics) and Igenomix (Vitrolife). Broad incumbents are Quest Diagnostics, BioReference Laboratories (OPKO Health) and Reprogenetics (Labcorp). Myome Sciences is listed as an emerging player. Thermo Fisher Scientific (Reproductive Health) is listed as an others.

Does JUNO Genetics have an API?

No public API is recorded for JUNO Genetics.

What industry is JUNO Genetics in?

JUNO Genetics's product category is Reproductive Genetic Testing. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IviglobaleducationBiotechnology and Artificial Intelligence in Reproductive MedicineThis article is a feature/interview with Dr. Antonio Capalbo, Chief Scientific Officer of Juno Genetics, discussing the integration of biotechnology and artificial intelligence in reproductive medicine. It covers advancements in IVF techniques including embryo selection at the blastocyst stage, vitrification for cryopreservation, and preimplantation genetic testing (PGT). The article also explores future applications such as whole genome sequencing, AI-driven predictive models for treatment personalization, gene therapy for genetic infertility, and ovarian rejuvenation techniques.PR NewswireGroundbreaking PGT-A Genetic Test Research Receives Prestigious Investigator Achievement AwardDr. Julia Kim won the 2022 Investigator Achievement Award from Fertility and Sterility journal for her landmark study on preimplantation genetic testing for aneuploidy (PGT-A), conducted during her fellowship at Reproductive Medicine Associates in collaboration with Juno Genetics. The research demonstrated nearly 100% concordance rates for euploid and aneuploid PGTSeq results, but found poor reproducibility for mosaic diagnoses at only 2%, raising questions about the clinical utility of mosaicism reporting. Additional data presented at the ASRM conference on nearly 5,000 embryo transfers found no statistically significant difference in pregnancy rates between embryos with and without mosaic findings, suggesting such embryos may be unnecessarily excluded from patient use.